CU20120057A7 - Composición vacunal contra el virus del dengue, kit y plásmido - Google Patents

Composición vacunal contra el virus del dengue, kit y plásmido

Info

Publication number
CU20120057A7
CU20120057A7 CU2012000057A CU20120057A CU20120057A7 CU 20120057 A7 CU20120057 A7 CU 20120057A7 CU 2012000057 A CU2012000057 A CU 2012000057A CU 20120057 A CU20120057 A CU 20120057A CU 20120057 A7 CU20120057 A7 CU 20120057A7
Authority
CU
Cuba
Prior art keywords
dengue virus
dna vaccines
plasid
kit
serotypes
Prior art date
Application number
CU2012000057A
Other languages
English (en)
Other versions
CU24060B1 (es
Inventor
Ada María De Barcelos Alves
Adriana De Souza Azevedo
Ricardo Galler
Marcos Da Silva Freire
Original Assignee
Fundação Oswaldo Cruz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43825448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20120057(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fundação Oswaldo Cruz filed Critical Fundação Oswaldo Cruz
Publication of CU20120057A7 publication Critical patent/CU20120057A7/es
Publication of CU24060B1 publication Critical patent/CU24060B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un método para inducir la respuesta inmune contra el virus del dengue basado en vacunas de ADN y virus quiméricos 17D en inmunizaciones combinadas o coadministradas. rambién están dentro del objeo de la invención vacunas de ADN contra los cuatro serotipos del virus del dengue a partir de la construcción de distintos plásmidos recombinantes conteniendo el gen que codifica la proteína E, o sólamente la secuencia que corresponde al dominio III de esta proteína, a partir de cada serotipo viral del virus dengue (DENV1-4). La invención suministra aún, una composición vacunal consistiendo en (a) vacunas de ADN contra los cuatro serotipos del virus dengue, (b) virus quiméricos abarcando el virus vacunal de fiebre amarilla 17D modificado, y (c) un vehículo farmacéuticamente aceptable, está incluido en el objeto de protección.
CU20120057A 2009-10-01 2012-04-02 Composición vacunal contra el virus del dengue, kit y plásmido CU24060B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI0904020A BRPI0904020B8 (pt) 2009-10-01 2009-10-01 composição vacinal contra o vírus da dengue, e, kit
PCT/BR2010/000323 WO2011038473A1 (pt) 2009-10-01 2010-08-01 Método, kit, plasmídeo e composição para induzir resposta imune contra virus da dengue baseado em vacinas de dna e vírus quiméricos

Publications (2)

Publication Number Publication Date
CU20120057A7 true CU20120057A7 (es) 2013-01-30
CU24060B1 CU24060B1 (es) 2014-12-26

Family

ID=43825448

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20120057A CU24060B1 (es) 2009-10-01 2012-04-02 Composición vacunal contra el virus del dengue, kit y plásmido

Country Status (10)

Country Link
US (1) US10357558B2 (es)
EP (1) EP2484376A4 (es)
CN (1) CN102711817B (es)
BR (1) BRPI0904020B8 (es)
CL (1) CL2012000783A1 (es)
CO (1) CO6541529A2 (es)
CU (1) CU24060B1 (es)
EC (1) ECSP12012131A (es)
PE (2) PE20161094A1 (es)
WO (1) WO2011038473A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968516B1 (en) 2013-03-15 2022-01-12 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
JP2016523251A (ja) 2013-06-21 2016-08-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． デングウイルスワクチン組成物およびその使用方法
ITRM20130458A1 (it) 2013-08-05 2015-02-05 Internat Ct For Genetic En Gineering And Vaccino genetico anti-dengue virus basato sugli ectodomini della proteina envelope
ES2981476T3 (es) * 2014-12-22 2024-10-09 Merck Sharp & Dohme Llc Composiciones de vacunas contra el virus del dengue y métodos de uso de las mismas
EP3846849A1 (en) 2018-09-05 2021-07-14 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455509B1 (en) * 1996-06-04 2002-09-24 The United States Of America As Represented By The Secretary Of The Navy Dengue nucleic acid vaccines that induce neutralizing antibodies
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
BRPI9701774B8 (pt) 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US6881723B1 (en) * 1998-11-05 2005-04-19 Powderject Vaccines, Inc. Nucleic acid constructs
US7476390B2 (en) * 2002-02-26 2009-01-13 Maxygen, Inc. Flavivirus antigens
JP5227172B2 (ja) 2005-08-10 2013-07-03 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー デングウイルス感染に対するワクチン接種
ZA200802176B (en) * 2005-08-10 2009-08-26 Acambis Inc Vaccination against dengue virus infection
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
ES2517615T3 (es) * 2006-11-09 2014-11-03 The United States Of America As Represented By The Secretary Of The Navy Inducción de una respuesta inmunitaria frente al virus del dengue usando un enfoque de sensibilización-refuerzo
KR101686942B1 (ko) 2008-01-11 2016-12-28 이노비오 파마수티컬즈, 인크. 뎅기 바이러스 다중 서브타입에 대항하는 신규한 백신

Also Published As

Publication number Publication date
BRPI0904020A2 (pt) 2011-06-14
CN102711817A (zh) 2012-10-03
US20120251570A1 (en) 2012-10-04
BRPI0904020B8 (pt) 2021-05-25
CL2012000783A1 (es) 2013-03-22
WO2011038473A1 (pt) 2011-04-07
EP2484376A1 (en) 2012-08-08
PE20121171A1 (es) 2012-08-30
CO6541529A2 (es) 2012-10-16
PE20161094A1 (es) 2016-10-22
BRPI0904020B1 (pt) 2019-11-12
ECSP12012131A (es) 2013-02-28
CU24060B1 (es) 2014-12-26
WO2011038473A8 (pt) 2012-07-19
US10357558B2 (en) 2019-07-23
CN102711817B (zh) 2016-10-26
EP2484376A4 (en) 2014-01-22

Similar Documents

Publication Publication Date Title
CU20120057A7 (es) Composición vacunal contra el virus del dengue, kit y plásmido
CO2018005229A2 (es) Vacuna de virus sincitial respiratorio
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
MX2010007461A (es) Nuevas vacunas contra multiples subtipos del virus del dengue.
MX339241B (es) Vacunas novedosas contra sub-tipos multiples de virus de influenza.
MX347997B (es) Vacunas aviares vectorizadas con el virus de la enfermedad de newcastle.
MX2009010549A (es) Virus atenuados utiles para vacunas.
JP2015524421A5 (es)
MX345150B (es) Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h5n1 y h1n1.
JP2017526689A5 (es)
CO7461133A2 (es) Parvovirus 5a porcino, métodos de uso y vacuna
NI201700080A (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas.
CO6670515A2 (es) Vectores de parapoxvirus
AR067439A1 (es) Virus quimericos antigenicos de virus de encefalitis de st. louis/virus dengue tipo 4
CO6700818A2 (es) Vectores de parapoxvirus
AR066823A1 (es) Aumento del rendimiento en plantas por modulacion del factor zmrr10-p de transcripcion de garp
Mooney et al. Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses
CU24188B1 (es) Composición vacunal contra el virus dengue
AR130779A1 (es) Vacunas de combinación
Guirakhoo Replication-competent Viral Vectors

Legal Events

Date Code Title Description
FG Grant of patent